FY2030 Earnings Estimate for Aemetis Issued By HC Wainwright

Aemetis, Inc (NASDAQ:AMTXFree Report) – Equities research analysts at HC Wainwright dropped their FY2030 earnings per share (EPS) estimates for shares of Aemetis in a research note issued on Monday, May 11th. HC Wainwright analyst A. Dayal now expects that the specialty chemicals company will post earnings of $2.87 per share for the year, down from their prior estimate of $3.05. The consensus estimate for Aemetis’ current full-year earnings is ($1.08) per share.

Aemetis (NASDAQ:AMTXGet Free Report) last posted its earnings results on Thursday, May 7th. The specialty chemicals company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The business had revenue of $54.62 million during the quarter, compared to analyst estimates of $66.70 million.

Several other analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Aemetis from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aemetis in a research report on Monday, April 20th. Loop Capital set a $1.75 price objective on Aemetis in a research note on Thursday, March 12th. Finally, Ascendiant Capital Markets boosted their target price on Aemetis from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.58.

Check Out Our Latest Stock Report on AMTX

Aemetis Trading Down 10.4%

AMTX stock opened at $2.32 on Tuesday. The firm has a 50 day moving average of $2.53 and a 200-day moving average of $1.97. Aemetis has a 12 month low of $1.30 and a 12 month high of $3.80. The firm has a market capitalization of $163.26 million, a P/E ratio of -1.95 and a beta of 1.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC raised its position in Aemetis by 462.6% during the fourth quarter. Squarepoint Ops LLC now owns 177,215 shares of the specialty chemicals company’s stock valued at $246,000 after purchasing an additional 145,716 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Aemetis in the 2nd quarter valued at $64,000. XTX Topco Ltd bought a new position in shares of Aemetis during the 4th quarter valued at $52,000. Caitong International Asset Management Co. Ltd bought a new stake in Aemetis in the fourth quarter worth $49,000. Finally, Engineers Gate Manager LP bought a new position in shares of Aemetis during the second quarter valued at about $42,000. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

About Aemetis

(Get Free Report)

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

Further Reading

Earnings History and Estimates for Aemetis (NASDAQ:AMTX)

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.